Wanda, a NetScientific Inc. portfolio company that commercializes transformative biomedical and healthcare technologies has signed a collaborative deal with Dignity Health, to launch OncoVerse, a digital health oncology care platform. OncoVerse was initially conceived by a Dignity Health physician who wanted a tool to improve team collaboration, especially when evaluating a complex cancer case and determining the appropriate treatment plan.
OncoVerse is a software platform designed to enable a patient’s care team to collaborate in real-time, allowing clinicians across all disciplines to work together to determine the most effective treatment plan for cancer patients. The software will also help to reduce administrative costs associated with high quality cancer care.
Dignity Health is a network of nearly 9,000 physicians and more than 400 care centers, including hospitals and primary care clinics spanning 21 US states. The OncoVerse platform will support Dignity Health’s physicians and healthcare professionals to enable them to make informed decisions on the treatment of cancer patients. It will also enable Dignity Health to expand the geographic reach of its clinical decision-making support system to reach the most rural and remote areas – allowing all patients to benefit from insights previously only shared at large medical centers.
Wanda and Dignity Health are shareholders in Oncoverse LLC, a San Francisco based digital health company, and the creator of the OncoVerseTM software platform. Wanda and Dignity Health will jointly market the Oncoverse platform to other oncology programs across the US later in 2016 to earn revenues through uptake of the platform. The relationship with Dignity Health will also allow for cross-marketing of existing and future Wanda products.
Facilitating individualized cancer decision support is becoming increasingly important as cancer therapies advance. Wanda’s core technology aims to improve the efficiency and effectiveness of the management of chronic conditions.
“We are thrilled to partner with Dignity Health to launch the OncoVerse product,” said Steve Curd, CEO of Wanda in the press announcement. “OncoVerse will streamline and support the decision making processes of Dignity Health’s physicians and other supporting health care professionals by ensuring that the entire care team has the right information at the right time, which reinforces the power of personalized medicine. As cancer therapies continue to advance, facilitating individualized cancer decision support is well-aligned with Wanda’s mission: improving the efficiency and effectiveness of the management of chronic conditions.”
